Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Prop 65 NRT Warning Rejection Should Be Given Deference, Firms Say

This article was originally published in The Tan Sheet

Executive Summary

FDA's view that a Prop 65 pregnancy warning on OTC nicotine replacement therapies is "without scientific foundation" should be given more weight, NRT firms assert in a brief filed in California Supreme Court Jan. 21
Advertisement

Related Content

NRT Firms’ Deference To “Informal” FDA Letters In Prop 65 Case Improper
NRT Firms’ Deference To “Informal” FDA Letters In Prop 65 Case Improper
NRT Firms’ Deference To “Informal” FDA Letters In Prop 65 Case Improper
Nicotine Replacement Therapy Prop 65 Warning Unfounded, FDA Tells Court
Prop 65 Smoking Cessation Warnings Not In Conflict With FDA Rules – Court
Prop 65 Smoking Cessation Warnings Not In Conflict With FDA Rules – Court
Smoking Cessation Patch, Gum Prop 65 Warning Federally Preempted - Court

Topics

Advertisement
UsernamePublicRestriction

Register

PS095110

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel